Session (CTI)

Issue • It takes increasingly innovative approaches to deliver further health gains for many therapy areas, but such approaches are inherently higher risk for manufacturers. • New pharmacological modalities benefits may go beyond the QALY so how can this be captured? How can this be fairly and transparently reflected in decision making? • With the aim of supporting the development and commercialisation of innovative technologies, should they be assigned additional value in HTA? • If it is progressive and appropriate to give additional willingness-to-pay to innovative therapies, should willingness-to-pay be lowered for non-innovative therapies? • How would we define 'innovative'? How do we stop all products having an ‘innovation’ claim, how do we define true innovation? • Would a higher willingness-to-pay for innovative therapies reflect public preferences? Overview This issue panel examines whether and how we should consider innovation in HTA, should true innovation be rewarded with a higher willingness-to-pay to recognise benefits outside the QALY. Prof Lieven Annemans (Belgium) will introduce the concept of paying more for innovation in HTA and frame the debate. Prof Lotte Steuten (Office of Health Economics) will present the rationale for increased flexibilities and higher willingness-to-pay for innovative treatments. Prof Mark Sculpher (UK) will articulate the case against, including considering the opportunity cost for other patients and the potential for double counting. Natalie Bennett (Industry representative) will highlight the rationale for change and inclusion, setting out the need for transparency and fairness of consideration.